Duac® fixed dose combination gel — Competitive Intelligence Brief

Duac® fixed dose combination gel (Duac® fixed dose combination gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination. Area: Dermatology.

marketed Topical antibiotic combination Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide) Dermatology Small molecule

Target snapshot

Duac® fixed dose combination gel (Duac® fixed dose combination gel) — GlaxoSmithKline. Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to kill acne-causing bacteria and reduce inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duac® fixed dose combination gel TARGET	Duac® fixed dose combination gel	GlaxoSmithKline	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Acnatac® Gel right face	Acnatac® Gel right face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Benzoyl peroxide with clindamycin	Benzoyl peroxide with clindamycin	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Clindamycin and BPO 5% gel	Clindamycin and BPO 5% gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)
Duac Gel	Duac Gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination class)

1. Stiefel, a GSK Company · 3 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. GWT-TUD GmbH · 2 drugs in this class
4. Sun Pharmaceutical Industries, Inc. · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of British Columbia · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. B. Braun Medical SA · 1 drug in this class
9. Watson Laboratories, Inc. · 1 drug in this class
10. Padagis LLC · 1 drug in this class